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Since the 1960’s, small cell lung cancer (SCLC) has been recognized as 
a distinct subtype of lung cancer with a unique sensitivity to chemo-
therapy (1). Multiple therapeutic agents and strategies tested over the 
last 3 decades result in a 1 year survival rate of 30-40% for patients 
with extensive stage disease (ED). Unfortunately, unlike other chemo-
therapy-sensitive cancers such as lymphoma and germ cell tumors, sig-
niﬁcant advances in the treatment of ED SCLC have stalled. Testing of 
“newer” chemotherapy agents such as epirubicin, ifosfamide, vinorel-
bine, the taxanes, and gemcitabine, have failed to improve survival 
compared with the older chemotherapy agents, cisplatin and etoposide 
(PE). In the U.S. PE for 4 cycles has been standard ﬁrst line therapy 
based upon the results of randomized trials which indicated that other 
regimens were not superior, but rather resulted in more inconvenience 
and toxicity (2).
Camptothecin is a plant alkaloid present in the Asian tree Camptotheca 
acuminata. Camptothecin was recognized as a potential anti-cancer 
drug based upon a screening program conducted by the U.S. National 
Cancer Institute in the 1960’s (3). During replication, DNA unwinds 
so that single strands serve as a template for synthesis of new DNA 
strands. Topoisomerase 1 plays a critical role in the cleavage of single 
DNA strands, necessary to allow the broken strand of DNA to rotate 
around the intact strand during DNA replication. Camptothecins target 
topoisomerase 1 by stabilizing the cleavable complex between topoi-
somerase 1 and DNA (4). Irinotecan, a water-soluble semi synthetic 
derivative of camptothecin, entered clinical trials in the 1980’s. Irino-
tecan is a prodrug of the metabolite, SN38, which has 2-3 logs greater 
activity than irinotecan. Importantly, SN-38 is cleared by uridine 
diphosphate glycosyltransferase 1 family polypeptide A1 (UGT1A1), 
an enzyme important for biliary glucuronidation. Patients with certain 
polymorphisms in the promoter region of UGT1A1 are at higher risk 
for diarrhea and neutropenia (5).
In 2002, Noda et al reported the results of a phase III trial from the 
Japanese Cooperative Oncology Group (JCOG) that compared treat-
ment with cisplatin plus either irinotecan or etoposide in 154 patients 
with ED SCLC (6). Median and 1 year survival was signiﬁcant im-
proved in the patients receiving the irinotecan-based regimen compared 
with PE (12.8 months vs. 9.4 months, 58.4% vs. 37.7%, respectively). 
Patients on the PE arm experienced more neutropenia and thrombocy-
topenia, while patients on the IP arm experienced more diarrhea. The 
study was discontinued early based upon the recommendation of a data 
monitoring committee. A phase III trial conducted in the U.S., Canada, 
and Australia, utilizing a different dose and schedule of irinotecan and 
cisplatin failed to conﬁrm a survival advantage for the IP arm over 
the EP arm (7). Despite a change in the dose and schedule of IP, rates 
of gastrointestinal toxicity, namely vomiting and diarrhea were not 
substantially reduced, although dose intensity was improved compared 
with the IP regimen utilized in the JCOG trial. While there are several 
plausible reasons to explain the disparate results from the two trials, 
known pharmacogenomic differences between North American and 
Japanese populations likely played a role in determining both toxicity 
and efﬁcacy proﬁles of IP. Speciﬁcally, polymorphisms in UGT1A1 are 
observed between patient populations. Low rates of Gilbert’s syndrome 
(decreased level of gene transcription of UGT1A1) are recognized 
in Asian populations (8). In one study in non-small cell lung cancer, 
patients with Gilbert’s syndrome experienced more toxicity and worse 
survival with IP (9). Differences in toxicity and efﬁcacy proﬁles 
amongst North American and Japanese patients utilizing the same 
drugs have been reported (10). Similarly, UGT1A1*6 and UGT1A9*22 
genotypes have recently been reported to be associated with irnotecan-
related toxicity, response, and survival in Korean patients (11).
While PE remains standard in the U.S. for now, IP is an equally ef-
fective alternative regimen against ED SCLC. The substitution of 
carboplatin for cisplatin in the IP regimen has been explored in phase 
II and randomized phase II studies. Progression free survival favored 
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carboplatin plus irinotecan over carboplatin plus etoposide in one 
study (12). Other randomized trials comparing these carboplatin-based 
regimens are being conducted. Furthermore, a phase I trial combining 
cisplatin plus etoposide plus irinotecan resulted in a 77% response rate 
and median survival time of 12 months in 31 evaluable patients from 
Greece (13). Further phase II/III evaluation of this three drug regimen 
are underway. Finally, irinotecan-based therapy is undergoing evalu-
ation in limited stage patients as induction therapy (IP followed by 
concurrent EP and radiation) as well as consolidation therapy (EP and 
concurrent radiation followed by IP) (14,15). Each of these strategies 
resulted in a median survival time of about 2 years in phase II studies.
In conclusion, irinotecan is an active drug against SCLC. The IP 
regimen appears more effective than EP in Asian patient populations, 
although these results have not been conﬁrmed in North American 
populations. A completed phase III study from the Southwest Oncology 
Group in the U.S. comparing IP versus EP, given in the identical dose 
and schedules as the Noda trial, will deﬁnitively address this issue. 
Studies evaluating the role of irinotecan in limited stage disease are 
underway.
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Despite the remarkable advances in the molecular biology of lung 
adenocarcinoma, surprisingly few studies are supported by carefully 
detailed pathologic data. Lung adenocarcinoma histologic subtyping 
continues to evolve following the 2004 WHO classiﬁcation. 1 The 
search for a clinically and biologically meaningful way to further 
characterize the mixed subtype adenocarcinomas needs to be based 
on careful attention to the histologic criteria being applied so the data 
can be compared to other studies. There are widely varying published 
results regarding the correlation of histologic subtypes with different 
molecular features including EGFR, k-RAS and gene expression proﬁl-
ing. The methods of some of these papers indicate varied pathologic 
deﬁnitions, suggesting that some of these differences may be attributed 
to interpretation of the histologic subtyping. Most articles also focus on 
a single subtype of lung adenocarcinoma, mostly bronchioloalveolar 
carcinoma (BAC), comparing this with all other adenocarcinomas. Fu-
ture molecular studies of lung adenocarcinoma should be accompanied 
by careful histologic subtyping of the tumors with attention not only to 
a single component such as BAC, but all histologic subtypes, noting the 
predominant pattern in mixed subtype tumors. 
Correlations between histology and molecular ﬁndings also vary de-
pending whether the study involves non-small cell carcinoma or purely 
adenocarcinoma. For example associations between EGFR mutations 
and non-smokers, female gender, Asian descent, and adenocarcinoma, 
particularly with BAC, are generally much stronger if all non-small cell 
carcinomas are studied. These correlations are often not as strong in 
studies of pure adenocarcinoma. 
While there is much emphasis in the literature about BAC and EGFR 
mutations, 2; 3 Tsao AS, Shigematsu H, Yoshida Y and Yatabe Y showed 
a lack of association of EGFR mutation with BAC subtype suggest-
ing an association with invasive adenocarcinoma rather than BAC. 4-7 
Kim, YH et al found that a dominant papillary subtype is a signiﬁcant 
predictor of response to geﬁtinib in adenocarcinoma of the lung. 8 K-ras 
mutations are associated with 73-100% of the mucinous type of BAC. 9
Gene proﬁling studies using cDNA arrays have consistently identiﬁed 
3-4 clusters among of lung adenocarcinomas. 10-12 This is a powerful 
tool that can measure the expression of thousands of genes in a single 
tumor sample, allowing for identiﬁcation of clinically and biologically 
subsets of tumors that are not apparent by usual clinical or pathologic 
methods. 13 Numerous studies have examined gene expression in a 
variety of subsets of lung cancer patients including non-small cell 
carcinoma, 14-20 adenocarcinoma, 10-12; 21-31 squamous cell carcinoma, 23; 
26; 32; 33 and small cell carcinoma. 34 Gene expression proﬁling of lung 
cancers has been used to identify sets of genes that predict prognosis, 
10; 17; 21; 25; 31; 32; 35-37 smoking status, 38 likelihood of metastases to lymph 
node15; 18; 29 or brain39, effectiveness of chemotherapy, 15; 40-42 tumor-stro-
mal interactions, 43; 44 and differential diagnosis with other tumors such 
as malignant mesothelioma. 45 In addition to cDNA microarrays, other 
